<DOC>
	<DOC>NCT01496274</DOC>
	<brief_summary>This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.</brief_summary>
	<brief_title>A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subjects, 12 to 65 years old Severe hemophilia B (FIX activity of â‰¤ 2%) Subjects who have received FIX products (plasmaderived and/or recombinant FIX) for &gt; 150 exposure days (EDs) No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX Written informed consent for study participation Ondemand subjects only, who have experienced a minimum average of 2 nontrauma induced bleeding episodes requiring treatment with a FIX product during the previous 6 or 3 months Known hypersensitivity to any FIX product or hamster protein Known congenital or acquired coagulation disorder other than congenital FIX deficiency HIV positive subjects with a CD4 count &lt; 200/mm3 Low platelet count, kidney or liver dysfunction Recent lifethreatening bleeding episode</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>